Bio-Rad Laboratories BIO Finance Lease, Right-of-Use Asset, Accumulated Amortization
Finance Lease, Right-of-Use Asset, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization?
- Bio-Rad Laboratories (BIO) reported finance lease, right-of-use asset, accumulated amortization of $6.4M in Q1 2026.
- How has Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization changed year-over-year?
- Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization decreased by 0.0% year-over-year, from $6.4M to $6.4M.
- What is the long-term trend for Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's finance lease, right-of-use asset, accumulated amortization has grown at a 5.1% compound annual growth rate (CAGR), from $5M to $6.4M.